Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma

被引：12
|
作者：
Sivaraj, Dharshan [1 ]
Green, Michael M. [1 ]
Kang, Yubin [1 ]
Long, Gwynn D. [1 ]
Rizzieri, David A. [1 ]
Li, Zhiguo [2 ]
Garrett, Anderson H. [1 ]
McIntyre, Jackie L. [1 ]
Chao, Nelson J. [1 ]
Gasparetto, Cristina [1 ]
机构：
[1] Duke Univ, Div Cellular Therapy, 2400 Pratt St, Durham, NC 27708 USA
[2] Dept Biostat & Bioinformat, 2424 Erwin Rd,Suite 1102,11086 Hock Plaza, Durham, NC 27705 USA
来源：
BLOOD CANCER JOURNAL | 2018年 / 8卷
关键词：
COMBINATION; LENALIDOMIDE; THERAPY;
D O I：
10.1038/s41408-018-0104-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Pomalidomide, Cyclophosphamide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Retrospective Single Center Experience
    Garderet, Laurent
    Polge, Emmanuelle
    Gueye, Mor Seny
    Kellil, Chaima
    Ova, Jeanny Guelongo Okouango
    Beohou, Eric
    Labopin, Myriam
    Mohty, Mohamad
    [J]. BLOOD, 2015, 126 (23)
  • [42] Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
    Fotiou, Despina
    Gavriatopoulou, Maria
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [43] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [44] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
    Richardson, Paul G.
    Attal, Michel
    Campana, Frank
    Le-Guennec, Solenn
    Hui, Ai-Min
    Risse, Marie-Laure
    Corzo, Kathryn
    Anderson, Kenneth C.
    [J]. FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
  • [45] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    [J]. BLOOD, 2014, 124 (21)
  • [46] OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Matsue, Kosei
    Sunami, Kazutaka
    Suzuki, Kenshi
    Takezako, Naoki
    Shinagawa, Atsushi
    Sakurai, Sanae
    Tamakoshi, Hiromi
    Biyukov, Tsvetan
    Peluso, Teresa
    Richardson, Paul
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E270 - E271
  • [47] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    [J]. HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [48] Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum
    Matsumura-Kimoto, Yayoi
    Kuroda, Junya
    Kaneko, Hitomi
    Kamitsuji, Yuri
    Fuchida, Shin-ichi
    Nakaya, Aya
    Shibayama, Hirohiko
    Uoshima, Nobuhiko
    Yokota, Isao
    Uchiyama, Hitoji
    Yagi, Hideo
    Kosugi, Satoru
    Matsui, Toshimitsu
    Ishikawa, Jun
    Matsuda, Mitsuhiro
    Ohta, Kensuke
    Iida, Masato
    Tanaka, Hirokazu
    Kobayashi, Masayuki
    Wada, Katsuya
    Shimazaki, Chihiro
    Nomura, Shosaku
    Imada, Kazunori
    Hino, Masayuki
    Matsumura, Itaru
    Kanakura, Yuzuru
    Takaori-Kondo, Akifumi
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (05) : 541 - 550
  • [49] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Dhakal, Binod
    D'Souza, Anita
    Hamadani, Mehdi
    Arce-Lara, Carlos
    Schroeder, Katrina
    Chhabra, Saurabh
    Shah, Nirav N.
    Gauger, Katelyn
    Keaton, Taylor
    Pasquini, Marcelo
    Hari, Parameswaran
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (8)
  • [50] Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
    Binod Dhakal
    Anita D’Souza
    Mehdi Hamadani
    Carlos Arce-Lara
    Katrina Schroeder
    Saurabh Chhabra
    Nirav N. Shah
    Katelyn Gauger
    Taylor Keaton
    Marcelo Pasquini
    Parameswaran Hari
    [J]. Blood Cancer Journal, 9
12345